ライブラリ登録: Guest
Begell Digital Portal Begellデジタルライブラリー 電子書籍 ジャーナル 参考文献と会報 リサーチ集
Critical Reviews™ in Eukaryotic Gene Expression
インパクトファクター: 1.841 5年インパクトファクター: 1.927 SJR: 0.649 SNIP: 0.516 CiteScore™: 1.96

ISSN 印刷: 1045-4403
ISSN オンライン: 2162-6502

Critical Reviews™ in Eukaryotic Gene Expression

DOI: 10.1615/CritRevEukaryotGeneExpr.2014011495
pages 281-286

Ductal Carcinoma In Situ: A Brief Review of Treatment Variation and Impacts on Patients and Society

Christine Vatovec
Rubenstein School of Environment and Natural Resources & College of Medicine, Vermont Cancer Center, University of Vermont, Burlington, Vermont
Mujde Z. Erten
Department of Surgery, College of Medicine, Vermont Cancer Center, University of Vermont, Burlington, Vermont; Global Health Economics Unit of the Vermont Center for Clinical and Translational Science, University of Vermont, Burlington, Vermont
Jane Kolodinsky
Department of Community Development and Applied Economics, University of Vermont, Burlington, Vermont
Phil Brown
Department of Sociology and Anthropology, Department of Health Sciences, Northeastern University, Boston, Massachusetts
Marie Wood
Department of Medicine, College of Medicine, Vermont Cancer Center, University of Vermont, Burlington, Vermont
Ted James
Department of Surgery, College of Medicine, Vermont Cancer Center, University of Vermont, Burlington, Vermont
Brian L. Sprague
Department of Surgery, College of Medicine, Vermont Cancer Center, University of Vermont, Burlington, Vermont

要約

Nearly 20% of all breast cancer cases are ductal carcinoma in situ (DCIS), with over 60,000 cases diagnosed each year. Many of these cases would never cause clinical symptoms or threaten the life of the woman; however, it is currently impossible to distinguish which lesions will progress to invasive disease from those that will not. DCIS is generally associated with an excellent prognosis regardless of the treatment pathway, but there is variation in treatment aggressiveness that seems to exceed the medical uncertainty associated with DCIS management. Therefore, it would seem that a significant proportion of women with DCIS receive more extensive treatment than is needed. This overtreatment of DCIS is a growing concern among the breast cancer community and has implications for both the patient (via adverse treatment-related effects, as well as out-of-pocket costs) and society (via economic costs and the public health and environmental harm resulting from health care delivery). This article discusses DCIS treatment pathways and their implications for patients and society and calls for further research to examine the factors that are leading to such wide variation in treatment decisions.

キーワード: breast cancer, DCIS, treatment

Articles with similar content:

Gemcitabine: A Review of Chemoresistance in Pancreatic Cancer
Critical Reviews™ in Oncogenesis, Vol.24, 2019, issue 2
Abdul Kareem Khan, Mamoon Ur Rashid, Ishtiaq Hussain, Sarfraz Ahmad, Asad Ur Rahman, Sundas Jehanzeb, Akriti Gupta Jain, Deepika Sarvepalli, Neelam Khetpal, Waqas Ullah, Badar Hasan
Review of Falls-Related Injuries
Critical Reviews™ in Physical and Rehabilitation Medicine, Vol.11, 1999, issue 1
Liz Reilly, Jai Kulkarni, Carolyn Hale
EEG-Based Neurofeedback: The Promise of Neurotechnology and Need for Neuroethically Informed Guidelines and Policies
Ethics in Biology, Engineering and Medicine: An International Journal, Vol.2, 2011, issue 3
Herbert Plischke, James Giordano, Donald DuRousseau
Rectal Cancer: What Patients Face and Express During Their Care Experience
Neuropathological Diseases, Vol.2, 2013, issue 1
Antonino De Paoli, Paola Zotti, Silvia Flora
Persistent Postnatal Perineal Pain and Dyspareunia: A Review of Physical Pathology and Treatment
Critical Reviews™ in Physical and Rehabilitation Medicine, Vol.11, 1999, issue 2
C. M. A. Glazener, E. J. C. Hay-Smith